Nutriband Chairman to Present at Emerging Growth Conference, Highlighting Abuse-Deterrent Technology
Nutriband Inc. Chairman Serguei Melnik will present at the Noble Capital Markets Emerging Growth Virtual Equity Conference, showcasing the company's AVERSA abuse-deterrent technology for transdermal pharmaceutical products.
Nutriband Inc. (NASDAQ: NTRB) announced that Chairman Serguei Melnik will present at Noble Capital Markets' Emerging Growth Virtual Equity Conference on Wednesday, October 8, 2025, at 3 p.m. ET. The virtual presentation represents a significant opportunity for the pharmaceutical development company to showcase its innovative technology platform to potential investors and the broader financial community.
The presentation will feature a fireside Q&A session with questions from the live virtual audience, providing direct engagement between company leadership and interested stakeholders. Registered investors will have the additional opportunity to schedule one-on-one meetings with Melnik, allowing for more detailed discussions about the company's progress and future prospects. Interested attendees can register at no cost via the conference's official site at https://ibn.fm/MQAEm.
A video webcast of the presentation will be available on Channelchek, Noble's investor portal, and will be archived for 90 days on both Channelchek.com and Nutriband's website at www.nutriband.com. This extended availability ensures that investors who cannot attend the live event will have ample opportunity to review the company's presentation and strategic direction.
The conference appearance comes as Nutriband continues development of its portfolio of transdermal pharmaceutical products. The company's lead product under development is an abuse-deterrent fentanyl patch incorporating its proprietary AVERSA abuse-deterrent technology. This technology represents a significant advancement in pharmaceutical safety, as it can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
The timing of this presentation is particularly relevant given the ongoing opioid crisis and increasing regulatory focus on abuse-deterrent formulations. Nutriband's technology addresses a critical need in the pharmaceutical industry for safer drug delivery systems, especially for potent medications like fentanyl that carry high risks of misuse. The company's approach could potentially set new standards for transdermal drug safety and open opportunities for licensing agreements with larger pharmaceutical companies.
Investors and industry observers can access the latest news and updates relating to NTRB in the company's newsroom at https://ibn.fm/NTRB. The virtual conference format allows for broader participation than traditional in-person events, potentially increasing the company's visibility among both institutional and retail investors during a period of significant development for its core technology platform.